{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:10:05Z","timestamp":1789906205415,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T00:00:00Z","timestamp":1371600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1475-2875-12-211","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T22:14:44Z","timestamp":1371680084000},"source":"Crossref","is-referenced-by-count":22,"title":["MMV in partnership: the Eurartesim\u00ae experience"],"prefix":"10.1186","volume":"12","author":[{"given":"David","family":"Ubben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,19]]},"reference":[{"key":"2823_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","volume":"12","author":"GM Nayyar","year":"2012","unstructured":"Nayyar GM, Breman JG, Newton PN, Herrington J: Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012, 12: 488-496. 10.1016\/S1473-3099(12)70064-6.","journal-title":"Lancet Infect Dis"},{"key":"2823_CR2","volume-title":"Antimalarial drug combination therapy: report of a WHO technicalconsultation","author":"WHO","year":"2001","unstructured":"WHO: Antimalarial drug combination therapy: report of a WHO technicalconsultation. 2001, Geneva: World Health Organization,"},{"key":"2823_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1086\/344647","volume":"35","author":"MB Denis","year":"2002","unstructured":"Denis MB, Davis TME, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D: Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodianchildren and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002, 35: 1469-1476. 10.1086\/344647.","journal-title":"Clin Infect Dis"},{"key":"2823_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2125.2003.01962.x","volume":"57","author":"H Karunajeewa","year":"2003","unstructured":"Karunajeewa H, Lim C, Hung T-Y, Ilett KF, Denis MB, Socheat D, Davis TME: Safety evaluation of fixed combination piperaquine plus dihydroartemisinin(Artekin\u00ae) in Cambodian children and adults withmalaria. Br J Clin Pharmacol. 2003, 57: 93-99. 10.1046\/j.1365-2125.2003.01962.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2823_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1086\/425015","volume":"190","author":"EA Ashley","year":"2004","unstructured":"Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung W, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ: Randomized, controlled dose-optimization studies ofdihydroartemisinin-piperaquine for the treatment of uncomplicatedmultidrug-resistant falciparum malaria in Thailand. J Infect Dis. 2004, 190: 1773-1782. 10.1086\/425015.","journal-title":"J Infect Dis"},{"key":"2823_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(03)15163-X","volume":"363","author":"TT Hien","year":"2004","unstructured":"Hien TT, Dolecek C, Mai PP, Dung NT, Truong NT, Thai LH, An DTH, Thanh TT, Stepniewska K, White NJ, Farrar J: Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodiumfalciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004, 363: 18-22. 10.1016\/S0140-6736(03)15163-X.","journal-title":"Lancet"},{"key":"2823_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1086\/432011","volume":"41","author":"EA Ashley","year":"2005","unstructured":"Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F: A randomized, controlled study of a simple, once-daily regimen ofdihydroartemisinin-piperaquine for the treatment of uncomplicated,multidrug-resistant falciparum malaria. Clin Infect Dis. 2005, 41: 425-432. 10.1086\/432011.","journal-title":"Clin Infect Dis"},{"key":"2823_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/trstmh\/trs019","volume":"107","author":"C Naing","year":"2013","unstructured":"Naing C, Mak JW, Aung K, Wong JY: Efficacy and safety of dihydroartemisinin-piperaquine for treatment ofuncomplicated Plasmodium falciparum malaria in endemic countries:meta-analysis of randomised controlled studies. Trans R Soc Trop Med Hyg. 2013, 107: 65-73. 10.1093\/trstmh\/trs019.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2823_CR9","volume-title":"Global plan for artemisinin resistance containment (GPARC)","author":"World Health Organization","year":"2011","unstructured":"World Health Organization: Global plan for artemisinin resistance containment (GPARC). 2011, [\n                    http:\/\/www.who.int\/malaria\/publications\/atoz\/artemisinin_resistance_containment_2011.pdf\n                    \n                  ]"},{"key":"2823_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00686-12","volume":"57","author":"R Leang","year":"2013","unstructured":"Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P: Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicatedPlasmodium falciparum and Plasmodium vivax inCambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013, 57: 818-826. 10.1128\/AAC.00686-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"2823_CR11","first-page":"281","volume":"95","author":"L Chen","year":"1982","unstructured":"Chen L, Qu FY, Zhou YC: Field observations on the antimalarial piperaquine. Chin Med J (Engl). 1982, 95: 281-286.","journal-title":"Chin Med J (Engl)"},{"key":"2823_CR12","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1242\/jeb.00653","volume":"206","author":"PL Olliaro","year":"2003","unstructured":"Olliaro PL, Taylor WRJ: Antimalarial compounds: from bench to bedside. J Exp Biol. 2003, 206: 3753-3759. 10.1242\/jeb.00653.","journal-title":"J Exp Biol"},{"key":"2823_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2165\/00003495-200565010-00004","volume":"65","author":"TM Davis","year":"2005","unstructured":"Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF: Piperaquine: a resurgent antimalarial drug. Drugs. 2005, 65: 75-87. 10.2165\/00003495-200565010-00004.","journal-title":"Drugs"},{"key":"2823_CR14","first-page":"45","volume":"4","author":"NQ Tip","year":"2001","unstructured":"Tip NQ, Trung TN, Tan TV, Phuc NT: A field trial of efficacy of CV8 in treatment of uncomplicatedfalciparum malaria. J Malar Parasit Dis Control. 2001, 4: 45-51.","journal-title":"J Malar Parasit Dis Control"},{"key":"2823_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-3156.2003.01180.x","volume":"9","author":"PT Giao","year":"2004","unstructured":"Giao PT, de Vries PJ, Hung LQ, Binh TQ, Nam NV, Kager PA: CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim andprimaquine, compared with atovaquone\u2013proguanil againstfalciparum malaria in Vietnam. Trop Med Int Health. 2004, 9: 209-216. 10.1046\/j.1365-3156.2003.01180.x.","journal-title":"Trop Med Int Health"},{"key":"2823_CR16","volume-title":"Update: Food and Drug Law, Regulation and Education","author":"L Li","year":"2011","unstructured":"Li L: China\u2019s new drug GMP: higher standards, new compliance philosophy. Update: Food and Drug Law, Regulation and Education. 2011, [\n                    http:\/\/www.fdli.org\/resources\/resources-list-view\/drugs,\/press-releases,policy-forums,update-magazine,whitepapers,\/page\/7\n                    \n                  ]"},{"key":"2823_CR17","doi-asserted-by":"publisher","first-page":"e6358","DOI":"10.1371\/journal.pone.0006358","volume":"4","author":"J Zwang","year":"2009","unstructured":"Zwang J, Ashley EA, Karema C, D\u2019Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F: Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria:a prospective multi-centre individual patient data analysis. PLoS One. 2009, 4: e6358-10.1371\/journal.pone.0006358.","journal-title":"PLoS One"},{"key":"2823_CR18","volume-title":"Case study of medicines for malaria venture","author":"M Kaminski","year":"2011","unstructured":"Kaminski M: Case study of medicines for malaria venture. Int Affairs Rev Winter. 2011, XX (1): [\n                    http:\/\/www.iar-gwu.org\/sites\/default\/files\/articlepdfs\/Morgan%20Kaminski%20-%20MMV.pdf\n                    \n                  ]"},{"key":"2823_CR19","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2006","unstructured":"WHO: Guidelines for the treatment of malaria. 2006, Geneva: World Health Organization"},{"key":"2823_CR20","doi-asserted-by":"publisher","first-page":"e11880","DOI":"10.1371\/journal.pone.0011880","volume":"5","author":"N Valecha","year":"2010","unstructured":"Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukittayakamee S: An open-label, randomised study of dihydroartemisinin-piperaquine versusartesunate-mefloquine for falciparum malaria in Asia. PLoS One. 2010, 5: e11880-10.1371\/journal.pone.0011880.","journal-title":"PLoS One"},{"key":"2823_CR21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1365-3156.2006.01671.x","volume":"11","author":"M Mayxay","year":"2006","unstructured":"Mayxay M, Thongpraseuth V, Khanthavong M, Lindega N, Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White NJ, Newton PN: An open, randomized comparison of artesunate plus mefloquine vs.dihydroartemisinin-piperaquine for the treatment of uncomplicatedPlasmodium falciparum malaria in the Lao People\u2019sDemocratic Republic (Laos). Trop Med Int Health. 2006, 11: 1157-1165. 10.1111\/j.1365-3156.2006.01671.x.","journal-title":"Trop Med Int Health"},{"key":"2823_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2165\/11203910-000000000-00000","volume":"72","author":"GM Keating","year":"2012","unstructured":"Keating GM: Dihydroartemisinin\/Piperaquine: a review of its use in the treatment ofuncomplicated Plasmodium falciparum malaria. Drugs. 2012, 72: 937-961. 10.2165\/11203910-000000000-00000.","journal-title":"Drugs"},{"key":"2823_CR23","doi-asserted-by":"publisher","first-page":"e7871","DOI":"10.1371\/journal.pone.0007871","volume":"4","author":"Q Bassat","year":"2009","unstructured":"Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, Nambozi M, Vale I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D\u2019Alessandro U: Dihydroartemisinin-piperaquine and artemether-lumefantrine for treatinguncomplicated malaria in African children: a randomised, non-inferioritytrial. PLoS One. 2009, 4: e7871-10.1371\/journal.pone.0007871.","journal-title":"PLoS One"},{"key":"2823_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1475-2875-10-50","volume":"10","author":"M Nambozi","year":"2011","unstructured":"Nambozi M, van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D\u2019Alessandro U: Safety and efficacy of dihydroartemisinin-piperaquine versusartemether-lumefantrine in the treatment of uncomplicated Plasmodiumfalciparum malaria in Zambian children. Malar J. 2011, 10: 50-10.1186\/1475-2875-10-50.","journal-title":"Malar J"},{"key":"2823_CR25","volume-title":"European medicines agency eurartesim assessment report, 23 June2011","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency: European medicines agency eurartesim assessment report, 23 June2011. 2011, European Medicines Agency,"},{"key":"2823_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/1475-2875-11-233","volume":"11","author":"N Gargano","year":"2012","unstructured":"Gargano N, Ubben D, Tommasini S, Bacchieri A, Corsi M, Bhattacharyya PC, Rao BH, Dubashi N, Dev V, Ghosh SK, Kumar A, Srivastava B, Valecha N: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versusartesunate-mefloquine in uncomplicated Plasmodium falciparummalaria in India. Malar J. 2012, 11: 233-10.1186\/1475-2875-11-233.","journal-title":"Malar J"},{"key":"2823_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.trstmh.2007.05.018","volume":"101","author":"HY Myint","year":"2007","unstructured":"Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ: Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007, 101: 858-866. 10.1016\/j.trstmh.2007.05.018.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2823_CR28","unstructured":"European Medicines Agency: Article 10A of Directive 2001\/83\/EC of the European parliament and of theCouncil of 6 November 2001 on the community code relating to medicinal productsfor human use. [\n                    http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/10\/WC500004481.pdf\n                    \n                  ],"},{"key":"2823_CR29","volume-title":"Guidance on a new therapeutic indication for a well-establishedsubstance","author":"European Commission Enterprise and Industry Directorate-General","year":"2007","unstructured":"European Commission Enterprise and Industry Directorate-General: Guidance on a new therapeutic indication for a well-establishedsubstance. 2007, Brussels: The European Commission,"},{"key":"2823_CR30","volume-title":"Eurartesim summary of product characteristics","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency: Eurartesim summary of product characteristics. 2011, [\n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001199\/human_med_001450.jsp&mid=WC0b01ac058001d124\n                    \n                  ]"},{"key":"2823_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1475-2875-11-110","volume":"11","author":"EY Klein","year":"2012","unstructured":"Klein EY, Lewis IA, Jung C, Llin\u00e1s M, Levin SA: Relationship between treatment-seeking behaviour and artemisinin drug qualityin Ghana. Malar J. 2012, 11: 110-10.1186\/1475-2875-11-110.","journal-title":"Malar J"},{"key":"2823_CR32","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1128\/AAC.05688-11","volume":"56","author":"F Borsini","year":"2012","unstructured":"Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, Funck-Brentano C: In vitro cardiovascular effects of dihydroartemisin-piperaquine combinationcompared with other antimalarials. Antimicrob Agents Chemother. 2012, 56: 3261-3270. 10.1128\/AAC.05688-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"2823_CR33","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni MF, Smith DL, Laxminarayan R: Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008, 105: 14216-14221. 10.1073\/pnas.0804628105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2823_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1475-2875-9-217","volume":"9","author":"DL Smith","year":"2010","unstructured":"Smith DL, Klein EY, McKenzie FE, Laxminarayan R: Prospective strategies to delay the evolution of anti-malarial drugresistance: weighing the uncertainty. Malar J. 2010, 9: 217-10.1186\/1475-2875-9-217.","journal-title":"Malar J"},{"key":"2823_CR35","first-page":"CD008492","volume":"7","author":"D Sinclair","year":"2011","unstructured":"Sinclair D, Gogtay N, Brand F, Olliaro P: Artemisinin-based combination therapy for treating uncomplicatedPlasmodium vivax malaria. Cochrane Database Syst Rev. 2011, 7: CD008492-","journal-title":"Cochrane Database Syst Rev"},{"key":"2823_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/B978-0-12-397900-1.00005-0","volume":"80","author":"NM Douglas","year":"2012","unstructured":"Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN: Chemotherapeutic strategies for reducing transmission of Plasmodiumvivax malaria. Adv Parasitol. 2012, 80: 271-300.","journal-title":"Adv Parasitol"},{"key":"2823_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1128\/AAC.01879-12","volume":"57","author":"I Sutanto","year":"2013","unstructured":"Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK: Randomized, open-label trial of primaquine against vivax malaria relapse inIndonesia. Antimicrob Agents Chemother. 2013, 57: 1128-1135. 10.1128\/AAC.01879-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"2823_CR38","volume-title":"Fact sheet, ACT prices under the affordable medicinesfacility-malaria","author":"The Global Fund","year":"2013","unstructured":"The Global Fund: Fact sheet, ACT prices under the affordable medicinesfacility-malaria. 2013, [\n                    http:\/\/www.theglobalfund.org\/en\/amfm\/\n                    \n                  ],"},{"key":"2823_CR39","first-page":"551","volume":"166","author":"Price RN (on behalf of The WWARN DHA-PQP Dose Impact Study Group)","year":"2012","unstructured":"Price RN (on behalf of The WWARN DHA-PQP Dose Impact Study Group): Assessing the effect of the recommended dihydroartemisinin-piperaquine dosingregimen on the risk of treatment failure in patients diagnosed withuncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2012, 166: 551-","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2875-12-211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1475-2875-12-211\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2875-12-211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:25:17Z","timestamp":1548116717000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/1475-2875-12-211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,19]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2823"],"URL":"https:\/\/doi.org\/10.1186\/1475-2875-12-211","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,19]]},"article-number":"211"}}